Moomoo AI 已提取核心信息
TC BioPharm (Holdings) PLC, a clinical-stage biotechnology company, has successfully regained compliance with the Nasdaq minimum bid price requirement, as confirmed on January 2, 2024. The company had previously been notified by Nasdaq on June 22, 2023, that it did not meet the minimum bid price of $1.00 for 30 consecutive business days. To address this, TC BioPharm was required to maintain a closing bid price of at least $1.00 for 10 consecutive business days. This condition was fulfilled on December 29, 2023, leading to the company's compliance with Nasdaq Listing Rule 5550(a)(2). The company issued a press release on January 4, 2024, to announce the regained compliance. TC BioPharm focuses on developing allogeneic gamma-delta T cell therapies for cancer treatment and is conducting clinical trials for its product line, including a Phase 2b/3 pivotal trial for OmnImmune® in the treatment of acute myeloid leukemia.
TC BioPharm (Holdings) PLC, a clinical-stage biotechnology company, has successfully regained compliance with the Nasdaq minimum bid price requirement, as confirmed on January 2, 2024. The company had previously been notified by Nasdaq on June 22, 2023, that it did not meet the minimum bid price of $1.00 for 30 consecutive business days. To address this, TC BioPharm was required to maintain a closing bid price of at least $1.00 for 10 consecutive business days. This condition was fulfilled on December 29, 2023, leading to the company's compliance with Nasdaq Listing Rule 5550(a)(2). The company issued a press release on January 4, 2024, to announce the regained compliance. TC BioPharm focuses on developing allogeneic gamma-delta T cell therapies for cancer treatment and is conducting clinical trials for its product line, including a Phase 2b/3 pivotal trial for OmnImmune® in the treatment of acute myeloid leukemia.
正如2024年1月2日确认的那样，临床阶段的生物技术公司TC Biopharm（Holdings）PLC已成功恢复对纳斯达克最低出价要求的遵守。纳斯达克此前曾于2023年6月22日通知该公司，该公司连续30个工作日未达到1.00美元的最低出价。为了解决这个问题，TC BioPharm必须连续10个工作日将收盘价维持在至少1.00美元。该条件已于2023年12月29日得到满足，这使该公司遵守了纳斯达克上市规则5550（a）（2）。该公司于2024年1月4日发布新闻稿，宣布恢复合规。TC BioPharm专注于开发用于癌症治疗的异基因伽玛-德尔塔T细胞疗法，并正在对其产品线进行临床试验，包括一项用于治疗急性髓系白血病的OmnImmune® 的2b/3期关键试验。
正如2024年1月2日确认的那样，临床阶段的生物技术公司TC Biopharm（Holdings）PLC已成功恢复对纳斯达克最低出价要求的遵守。纳斯达克此前曾于2023年6月22日通知该公司，该公司连续30个工作日未达到1.00美元的最低出价。为了解决这个问题，TC BioPharm必须连续10个工作日将收盘价维持在至少1.00美元。该条件已于2023年12月29日得到满足，这使该公司遵守了纳斯达克上市规则5550（a）（2）。该公司于2024年1月4日发布新闻稿，宣布恢复合规。TC BioPharm专注于开发用于癌症治疗的异基因伽玛-德尔塔T细胞疗法，并正在对其产品线进行临床试验，包括一项用于治疗急性髓系白血病的OmnImmune® 的2b/3期关键试验。
有用
没用